From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.
|
Synonyms: Braftovi® | LGX-818 | LGX818
encorafenib is an approved drug (FDA and EMA (2018))
Compound class:
Synthetic organic
Comment: Encorafenib (LGX-818) is an orally available BRAF kinase inhibitor with antineoplastic activity.
|
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| Encorafenib inhibits the BRAFV600E kinase with an IC50 of 4 nM [2]. |